Unknown

Dataset Information

0

Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin.


ABSTRACT: BACKGROUND:Breast cancer often metastasizes into bone and leads to osteolytic lesions. The underlying mechanisms, however, are complex and not fully understood. Syndecan-1 is a proteoglycan that has various functions relevant for tumor progression including cell-cell communication and cell-matrix interactions. Moreover, its two glycosaminoglycan-binding sites suggest that it may interfere with glycoproteins such as osteoprotegerin, a potent inhibitor of osteoclastogenesis. Thus, we hypothesize that tumor-derived syndecan-1 alters osteoclast biology by modulating osteoprotegerin. METHODS:Syndecan-1 expression was down-regulated via siRNA and the cell fate of the breast cancer cell lines MCF-7, T-47D, and MDA-MB-231 was investigated. Furthermore, we determined the regulation of syndecan-1 by dexamethasone, a commonly used antiemetic in breast cancer therapy. Additionally, we analyzed the genesis and activity of osteoclasts in indirect co-culture experiments using supernatants from MCF-7 cells with deficient and sufficient levels of syndecan-1. RESULTS:Dexamethasone time- and dose-dependently increased syndecan-1 expression up to 4-fold but did not alter cell behavior. Syndecan-1 up-regulation did not affect the survival or migration of breast cancer cells. Depletion of syndecan-1 using siRNA led to decreased vitality of progesterone receptor-positive cell lines. In MCF-7 cells osteoprotegerin production was up-regulated 2.5-fold after syndecan-1 knock-down. The culture of osteoclast precursors with the supernatant of MCF-7 cells with reduced syndecan-1 levels suppressed osteoclast formation and activity by 21% and 23%, respectively. Adding neutralizing antibodies to osteoprotegerin to the breast cancer supernatants reversed osteoclastogenesis. CONCLUSION:Thus, we identified tumor-derived syndecan-1 as a novel positive regulator of osteoclastogenesis and new player in the tumor-bone dialog.

SUBMITTER: Benad-Mehner P 

PROVIDER: S-EPMC4723417 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin.

Benad-Mehner Peggy P   Thiele Stefanie S   Rachner Tilman D TD   Göbel Andy A   Rauner Martina M   Hofbauer Lorenz C LC  

Journal of bone oncology 20131115 1


<h4>Background</h4>Breast cancer often metastasizes into bone and leads to osteolytic lesions. The underlying mechanisms, however, are complex and not fully understood. Syndecan-1 is a proteoglycan that has various functions relevant for tumor progression including cell-cell communication and cell-matrix interactions. Moreover, its two glycosaminoglycan-binding sites suggest that it may interfere with glycoproteins such as osteoprotegerin, a potent inhibitor of osteoclastogenesis. Thus, we hypot  ...[more]

Similar Datasets

| S-EPMC4505439 | biostudies-literature
| S-EPMC5429884 | biostudies-literature
| S-EPMC3775372 | biostudies-literature
| S-EPMC8661028 | biostudies-literature
| S-EPMC7327144 | biostudies-literature
| S-EPMC4674721 | biostudies-literature
| S-EPMC1850124 | biostudies-literature
| S-EPMC4200482 | biostudies-literature
2022-12-22 | GSE184253 | GEO
| S-EPMC4215719 | biostudies-literature